Effects of sufentanil in combination with dexmedetomidine for patient-controlled intravenous analgesia after renal transplantation
Abstract
Background/Aim. Nowadays, the most convenient analgesic method is patient-controlled intravenous injection of one or more adjuvant drugs. The aim of our study was to evaluate the effects of sufentanil plus dexmedetomidine for patient-controlled intravenous analgesia (PCIA) after renal transplantation. Methods. Seventy-eight patients receiving living-related renal transplantation under general anesthesia were selected. Radioisotope scanning was performed, and the single glomerular filtration rate of the unilateral kidney was ≥ 40 mL/min/1.73 m2. The control group (CG) and observation group (OG) (39 patients in each group) were analgesic with sufentanil and sufentanil plus dexmedetomidine, respectively. When the Visual Analogue Scale (VAS) score exceeded 4 points, 0.05 mg/kg oxycodone was intravenously injected for remedial analgesia. Plasma levels of endothelin, urea nitrogen, and creatinine were measured by radioimmunoassay. Heart rate (HR), mean arterial pressure, oxygen saturation, VAS score, and sedation score were recorded before anesthesia and after surgery. Analgesic remediation rate, number of effectively pressing the PCIA pump, and incidence rate of adverse reactions within 48 hrs after surgery were recorded. Results. HR of OG was significantly lower than that of CG 6 and 12 hrs after surgery (p < 0.05). VAS score of OG was lower than that of CG 6, 12, and 24 hrs after surgery (p < 0.05). OG had a lower postoperative remedial rate, number of effectively pressing the PCIA pump, and incidence rates of nausea and vomiting (p < 0.05) compared to CG. Endothelin, urea nitrogen, and creatinine levels significantly decreased after surgery compared with those before anesthesia (p < 0.05). The levels of OG were lower than those of CG at each time point after surgery (p < 0.05). Conclusion. Sufentanil plus dexmedetomidine can be safely and effectively used for PCIA after renal transplantation, with superior outcomes to those of sufentanil alone.
References
Kotsis F, Bächle H, Altenbuchinger M, Dönitz J, Njipouombe Nsangou YA, Meiselbach H, et al. Expectation of clinical deci-sion support systems: a survey study among nephrologist end-users. BMC Med Inform Decis Mak 2023; 23(1): 239.
Shaheen FAM, Al-Attar B, Ahmad MK, Follero PM. Burden of disease: Prevalence and incidence of endstage renal disease in Middle Eastern countries. Clin Nephrol 2020; 93(1): 120–3.
Saumoy M, Jesudian AB, Aden B, Serur D, Sundararajan S, Sivan-anthan G, et al. High prevalence of colon adenomas in end-stage kidney disease patients on hemodialysis undergoing renal transplant evaluation. Clin Transplant 2016; 30(3): 256–62.
Al-Rashid F, Bienholz A, Hildebrandt HA, Patsalis PC, Totzeck M, Kribben A, et al. Transfemoral transcatheter aortic valve implantation in patients with end-stage renal disease and kid-ney transplant recipients. Sci Rep 2017; 7(1): 14397.
Wei S, Qiu CY, Jin Y, Liu TT, Hu WP. Dexmedetomidine In-hibits ASIC Activity via Activation of α2A Adrenergic Recep-tors in Rat Dorsal Root Ganglion Neurons. Front Pharmacol 2021; 12: 685460.
Nie Z, Cui X, Zhang R, Li Z, Lu B, Li S, et al. Effectiveness of Patient-Controlled Intravenous Analgesia (PCIA) with sufen-tanil background infusion for post-cesarean analgesia: a ran-domized controlled trial. J Pain Res 2022; 15: 1355–64.
Emons MI, Maring M, Stamer UM, Pogatzki-Zahn E, Petzke F, Erlenwein J. Safety and monitoring of patient-controlled intra-venous analgesia: Clinical practice in German hospitals. An-aesthesist 2021; 70(6): 476–85. (German)
Nie Y, Tu W, Shen X, Yu W, Yu Y, Song X, et al. Dexme-detomidine added to sufentanil patient-controlled intravenous analgesia relieves the postoperative pain after cesarean deliv-ery: a prospective randomized controlled multicenter study. Sci Rep 2018; 8: 9952.
Kim J, Choi SM, Park YS, Lee CH, Lee SM, Yoo CG, et al. Dexmedetomidine versus midazolam for sedation during en-dobronchial ultrasound-guided transbronchial needle aspira-tion: A randomised controlled trial. Eur J Anaesthesiol 2021; 38(5): 534–40.
Karthik NM, Das SG, Johney J, George M, Issac E, Vasudevan A. Comparison of postoperative analgesia with two different doses of dexmedetomidine as an adjuvant to ropivacaine in adductor canal block for unilateral total knee replacement surgery: A randomized double-blinded study. J Anaesthesiol Clin Pharmacol 2022; 38(3): 428–33.
Bielka K, Kuchyn I, Babych V, Martycshenko K, Inozemtsev O. Dexmedetomidine infusion as an analgesic adjuvant during laparoscopic сholecystectomy: a randomized controlled study. BMC Anesthesiol 2018; 18(1): 44.
Feng M, Chen X, Liu T, Zhang C, Wan L, Yao W. Dexme-detomidine and sufentanil combination versus sufentanil alone for postoperative intravenous patient-controlled analgesia: a systematic review and meta-analysis of randomized controlled trials. BMC Anesthesiol 2019; 19(1): 81.
Han C, Lei D, Jiang W, Ren H, Su G, Feng S, et al. Pre-emptive dexmedetomidine decreases the incidence of chronic post hys-terectomy pain. Int J Clin Exp Med 2019; 12(1): 967–71.
Fernandez Rojas R, Brown N, Waddington G, Goecke R. A sys-tematic review of neurophysiological sensing for the assess-ment of acute pain. NPJ Digit Med 2023; 6(1): 76.
May ES, Tiemann L, Schmidt P, Nickel MM, Wiedemann N, Dresel C, et al. Behavioral responses to noxious stimuli shape the perception of pain. Sci Rep 2017; 7: 44083.
Wick EC, Grant MC, Wu CL. Postoperative Multimodal An-algesia Pain Management with Nonopioid Analgesics and Techniques. JAMA Surg 2017; 152(7): 691–7.
Deshler BJ, Rockenbach E, Patel T, Monahan BV, Poggio JL. Cur-rent update on multimodal analgesia and nonopiate surgical pain management. Curr Prob Surg 2023; 60(6): 101332.
Jiang H, Zheng Y, Liu C, Bao Y. Postoperative analgesia effects of sulfentanyl plus dexmedetomidine in patients received VATS. Pteridines 2020; 31(1): 55–60.
García-López C, Gómez-Huertas C, Sánchez-González JM, Borroni D, Rodríguez-Calvo-de-Mora M, Romano V, et al. Opioids and Ocular Surface Pathology: A Literature Review of New Treatments Horizons. J Clin Med 2022; 11(5): 1424.
Oshima H, Nakamura M, Watanabe O, Yamamura T, Funasaka K, Ohno E, et al. Dexmedetomidine provides less body motion and respiratory depression during sedation in double-balloon enteroscopy than midazolam. SAGE Open Med 2017; 5: 2050312117729920.
Tang C, Hu Y, Zhang Z, Wei Z, Wang H, Geng Q, et al. Dexme-detomidine with sufentanil in intravenous patient-controlled analgesia for relief from postoperative pain, inflammation and delirium after esophageal cancer surgery. Biosci Rep 2020; 40(5): BSR20193410.
Bamford NJ, Harris PA, Bailey SR. Circannual variation in plasma adrenocorticotropic hormone concentrations and dex-amethasone suppression test results in Standardbred horses, Andalusian horses and mixed-breed ponies. Aust Vet J 2020; 98(12): 616–21.
Yabeyu AB, Haile KT, Belay YB, Tegegn HG. Limited Public Knowledge of Chronic Kidney Disease in a Resource-Limited Setting: A Cross-Sectional Study. Int J Gen Med 2022; 15: 4997–5003.
Adeyomoye OI, Akintayo CO, Omotuyi KP, Adewumi AN. The bi-ological roles of urea: A review of preclinical studies. Indian J Nephrol 2022; 32(6): 539–45.
Nwogueze BC, Ofili IM, Nnama TN, Aloamaka CP. Oxidative stress-induced by different stressors alters kidney tissue anti-oxidant markers and levels of creatinine and urea: the fate of renal membrane integrity. Sci Rep 2023; 13(1): 13309.
Viderman D, Tapinova K, Nabidollayeva F, Tankacheev R, Abdild-in YG. Intravenous versus Epidural Routes of Patient-Controlled Analgesia in Abdominal Surgery: Systematic Re-view with Meta-Analysis. J Clin Med 2022; 11(9): 2579.
Su P, Li Z, Jia X, Peng X, Liu D, Xiao J, et al. A Response Sur-face Analysis of the Combination of Dexmedetomidine and Sufentanil for Attenuating the Haemodynamic Response to Endotracheal Intubation. Dose Response 2022; 20(2): 15593258221092367.